Cell Therapeutics (CTI) has announced high rates of complete remission in a new study to examine the efficacy of Opaxio (paclitaxel poliglumex), a new treatment for patients with cancer of the lower oesophagus.
Patients enrolled in the Phase II study showed high rates of remission when given Opaxio (paclitaxel poliglumex), a biologically enhanced paclitaxel, in combination with standard cisplatin and concurrent radiation.
Of the first 28 adenocarcinoma patients undergoing surgery, eight achieved pathologic complete remission and no patients required a feeding tube, which is the norm for standard regimen treatments.
Brown University Oncology Group head Howard Safran said that the preclinical profile is being validated by the high rates of pathologic complete remission and low rates of severe regional side effects observed in this Phase II study.
"Our results justify proceeding to a randomised, controlled trial to definitively prove the impressive clinical benefit we have observed in our experience with this novel bioengineered paclitaxel agent," Safran said.